Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update (in Eng). J Oral Maxillofac Surg 80:920–943. https://doi.org/10.1016/j.joms.2022.02.008

Article  PubMed  Google Scholar 

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117. https://doi.org/10.1016/s0278-2391(03)00720-1

Article  PubMed  Google Scholar 

Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU (2022) Interventions for managing medication-related osteonecrosis of the jaw (in Eng). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012432.pub3

Article  PubMed  PubMed Central  Google Scholar 

Disel U, Besen AA, Özyi̇lkan Ö, Er E, Canpolat T (2012) A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol https://doi.org/10.1016/j.oraloncology.2011.07.030

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized Phase II Trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates (in Eng). J Clin Oncol 27:1564–1571. https://doi.org/10.1200/jco.2008.19.2146

Article  CAS  PubMed  Google Scholar 

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours (in Eng). Health Technol Assess 17:1–386. https://doi.org/10.3310/hta17290

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (in Eng). Osteoporos Int (Osteoporos Int) 19:733–759. https://doi.org/10.1007/s00198-007-0540-8

Article  CAS  PubMed  Google Scholar 

Allen MR (2009) Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench (in Eng). Cells Tissues Organs 189:289–294. https://doi.org/10.1159/000151371

Article  CAS  PubMed  Google Scholar 

Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692. https://doi.org/10.1016/j.bone.2010.11.020

Article  CAS  PubMed  Google Scholar 

Pimolbutr K, Porter S, Fedele S (2018) Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature. Biomed Res Int 2018:8071579. https://doi.org/10.1155/2018/8071579

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body J-J, Migliorati C, Lalla RV, for the MBSG (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383–394. https://doi.org/10.1007/s00520-018-4501-x

Article  PubMed  Google Scholar 

Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Cranio-Maxillofac Surg 45:1493–1502. https://doi.org/10.1016/j.jcms.2017.05.028

Article  Google Scholar 

Peer A, Khamaisi M (2015) Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res 94:252–260. https://doi.org/10.1177/0022034514560768

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park S-M, Lee J-H (2022) Effects of Type 2 Diabetes mellitus on osteoclast differentiation, activity, and cortical bone formation in POSTmenopausal MRONJ patients. J Clin Med 11:2377

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP (2010) The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy (in Eng). Curr Osteoporos Rep 8:40–48. https://doi.org/10.1007/s11914-010-0008-1

Article  PubMed  Google Scholar 

Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, Troeltzsch M, Pautke C, Ehrenfeld M (2021) Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ). Medicina 57:463

Article  PubMed  PubMed Central  Google Scholar 

Morita M, Iwasaki R, Sato Y, Kobayashi T, Watanabe R, Oike T, Nakamura S, Keneko Y, Miyamoto K, Ishihara K, Iwakura Y, Ishii K, Matsumoto M, Nakamura M, Kawana H, Nakagawa T, Miyamoto T (2017) Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis (in Eng). Sci Rep 7:46322. https://doi.org/10.1038/srep46322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soma T, Iwasaki R, Sato Y, Kobayashi T, Nakamura S, Kaneko Y, Ito E, Okada H, Watanabe H, Miyamoto K, Matsumoto M, Nakamura M, Asoda S, Kawana H, Nakagawa T, Miyamoto T (2021) Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw (in Eng). J Bone Miner Metab 39:372–384. https://doi.org/10.1007/s00774-020-01174-2

Article  CAS  PubMed  Google Scholar 

Soma T, Iwasaki R, Sato Y, Kobayashi T, Ito E, Matsumoto T, Kimura A, Miyamoto K, Matsumoto M, Nakamura M, Morita M, Asoda S, Kawana H, Nakagawa T, Miyamoto T (2022) Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics (in Eng). Sci Rep 12:19. https://doi.org/10.1038/s41598-021-03966-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Pu Y, Lu H, Zhao N, Wang Y, Guo Y, Guo C (2021) Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw. J Oral Microbiol 13:1851112. https://doi.org/10.1080/20002297.2020.1851112

Article  CAS  Google Scholar 

Hagino H, Jackson M, Gitlin M, Wessler Z (2021) Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in Japan: a simulation projection model from 2020 to 2040. Arch Osteoporos 16:156. https://doi.org/10.1007/s11657-021-01019-z

Article  PubMed  Google Scholar 

LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) Correction to: The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2243–2343. https://doi.org/10.1007/s00198-022-06479-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175–195. https://doi.org/10.1016/S0169-409X(00)00061-2

Article  CAS  PubMed  Google Scholar 

Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264. https://doi.org/10.1016/j.bone.2006.09.023

Article  CAS  PubMed  Google Scholar 

Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600–2602. https://doi.org/10.1210/endo-123-5-2600

Article  CAS  PubMed  Google Scholar 

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176. https://doi.org/10.1016/S0092-8674(00)81569-X

Article  CAS  PubMed  Google Scholar 

Kim H-W, Lee M-W, Lee J-H, Kim M-Y (2021) Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med 10:2988

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S-H, Choi S-Y, Bae M-S, Kwon T-G (2021) Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment. Maxillofac Plastic Reconstr Surg 43:24.